This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Trek Therapeutics, PBC
Drug Names(s): VX-497, MMPD
Description: Merimepodib targets hepatitis C indirectly through the inhibition of inosine monophosphate dehydrogenase.
Vertex and Trek Therapeutics
In July 2016, Trek Therapeutics announced that it acquired the worldwide development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties from Vertex Pharmaceuticals.
Vertex will be eligible to receive milestones and royalties based on successful development and commercialization of lomibuvir and merimepodib. Other terms were not disclosed.
Partners: Vertex Pharmaceuticals Incorporated
Additional information available to subscribers only: